Ophthalmology and Therapy最新文献

{"title":"Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.","authors":"Seenu M Hariprasad, Frank G Holz, Carl V Asche, Amine Issa, Oriol Mora, Simon Keady, Mourad F Rezk, Phil Sarocco, Steven Simoens","doi":"10.1007/s40123-025-01104-3","DOIUrl":"https://doi.org/10.1007/s40123-025-01104-3","url":null,"abstract":"<p><p>Retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, pose a significant global burden on individuals, families, and healthcare systems. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has become the standard treatment for retinal diseases, improving clinical outcomes, while delaying disease progression. Although effective, biologics are associated with high costs, which can lead to underutilisation and, consequently, suboptimal patient treatment outcomes, further contributing to healthcare costs. Additionally, the expansion in the elderly population is predicted to significantly increase costs and burden on healthcare systems due to retinal diseases, requiring effective strategies and the utilisation of emerging technologies that are crucial public health priorities for tackling global vision impairment. Recently, anti-VEGF biosimilars have been approved and are expected to provide a cost-effective alternative, while providing equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetic profiles as the reference product. The entry of biosimilars holds the promise of meeting some of these unmet needs, giving physicians and patients access to sustainable treatments that can provide cost-effective therapy, enabling savings to be reinvested into healthcare facilities. This article aims to review the impact of retinal diseases on clinical, social, and financial aspects of patient care, emphasising the potential value of biosimilars in ophthalmology.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Relative Peripheral Refraction and Efficacy of Myopia Control After Wearing Multifocal Soft Contact Lenses in Children.","authors":"Mengyao Xu, Yuxin Yang, Fengju Zhang, Yushan Xu, Yuyan Huang, Linlu Zhang, Jie Wen","doi":"10.1007/s40123-025-01096-0","DOIUrl":"https://doi.org/10.1007/s40123-025-01096-0","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigated the relationship between relative peripheral refraction (RPR), retinal choroidal vessel, and the growth rate of axial length (AL) in children with myopia wearing multifocal soft contact lenses (MiSight CLs).</p><p><strong>Methods: </strong>Forty-four eyes of 44 children with myopia wearing MiSight CLs were included in the study. RPRs and retinal choroidal vessel were measured at baseline, 3 months, 6 months, and 1 year using multispectral refraction topography (MRT) and optical coherence tomography angiograghy (OCTA). MRT presented RPR at different fields of view and OCTA presented retinal choroidal vessel characteristics centered on the macula. The correlation between the changes of RPR (ΔRPRs) and the growth rate of AL was analyzed.</p><p><strong>Results: </strong>The baseline AL, spherical equivalent, age, and average growth rate of AL of children are 24.76 ± 0.95 mm,  - 3.22 ± 1.77 D, 11.25 ± 2.42 years, and 0.22 ± 0.17 mm/year. At 3 months, TRPR (RPR of the circular visual field of 53° centered on macular fovea) (p = 0.0007), RPR-15 (p = 0.0042), RPR-30 (p = 0.0012), RPR-45 (p = 0.0031), and RPR-I (p = 0.0082) of children with myopia wearing MiSight CLs were significantly lower than baseline. The ΔRPR was negatively correlated with the growth rate of AL (ΔTRPR, r = - 0.43, p = 0.003; ΔRPR-45, r = - 0.43, p = 0.004; ΔRPR-I, r = - 0.35, p = 0.02; ΔRPR-N, r = - 0.32, p = 0.04). At 1 year, there was a significant difference in the retina vessel volume index compared to baseline (p = 0.0002).</p><p><strong>Conclusion: </strong>RPR showed significant changes at 3 months after wearing multifocal soft contact lenses, but noticeable changes in retinal vessel volume index occurred only at 1 year. MRT demonstrates a higher efficacy in the early detection of the effectiveness of myopia control measures.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Based Uveitis Diagnosis Through Retinal Vasculature Analysis: A Paradigm Shift in Ocular Tuberculosis.","authors":"Ikhwanuliman Putera, Jose D Vargas Quiros, Saskia M Rombach, Willem A Dik, P Martin van Hagen, Rina La Distia Nora","doi":"10.1007/s40123-025-01103-4","DOIUrl":"https://doi.org/10.1007/s40123-025-01103-4","url":null,"abstract":"<p><strong>Introduction: </strong>Diagnosis of uveitis is complex and often requires a series of investigations. Here, we utilize artificial intelligence (AI) for the quantitative analysis of retinal vasculature parameters from fundus photographs to differentiate confirmed ocular tuberculosis (TB) from QuantiFERON (QFT)-positive uveitis without another identifiable cause and ocular toxoplasmosis.</p><p><strong>Methods: </strong>Medical records and stored fundus images of patients with uveitis from a cohort at the Department of Ophthalmology, University of Indonesia, were analyzed. Three groups of patients were included: confirmed ocular TB (group A), QFT-positive uveitis (group B), and ocular toxoplasmosis (group C). Fundus images were processed using the Retinalysis models package for segmentation and quantification of retinal vasculature parameters.</p><p><strong>Results: </strong>The study included nine patients (13 eyes) in group A, 38 patients (48 eyes) in group B, and 26 patients (39 eyes) in group C. Significant differences were found in vein tortuosity parameter, in the eyes within group A showing lower tortuosity score compared to eyes within group B (p = 0.030) and group C (p = 0.013). The area under the curve (AUC) of vein tortuosity for group A compared to group B was 0.749 (95% confidence interval (CI): 0.606-0.892), with a sensitivity of 67.3% and specificity of 76.9%. The AUC of vein tortuosity for group A against group C was 0.803 (95% CI: 0.658-0.948), with a sensitivity of 74.4% and a specificity of 84.6%. In group A, uveitis resolution and vein tortuosity tended to be normalized upon complete antitubercular treatment.</p><p><strong>Conclusions: </strong>AI-based quantification of retinal vasculature parameters, particularly vein tortuosity, can differentiate confirmed ocular TB from QFT-positive uveitis and ocular toxoplasmosis. This approach shows promise for more precise diagnostic and therapeutic accuracy in ocular TB.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.","authors":"Piotr Wojciechowski, Marlena Wdowiak, Malgorzata Panek, Izabella Lunk, Joao Carrasco, Xin Zhang, Olivia Wu, Jean-François Korobelnik, Paolo Lanzetta","doi":"10.1007/s40123-025-01098-y","DOIUrl":"https://doi.org/10.1007/s40123-025-01098-y","url":null,"abstract":"<p><strong>Introduction: </strong>Aflibercept 8 mg administered in extended dosing intervals has shown non-inferior visual gains and comparable safety profile to aflibercept 2 mg in the PULSAR pivotal randomized clinical trial and has the potential to reduce the treatment burden of treating neovascular age-related macular degeneration (nAMD). This study aimed at gathering robust evidence to assess the comparative efficacy, safety, and treatment burden of aflibercept 8 mg against other anti-vascular endothelial growth factor (VEGF) agents as ranibizumab, brolucizumab, faricimab, and bevacizumab in patients with nAMD.</p><p><strong>Methods: </strong>A systematic literature review (SLR) was conducted, targeting clinical trials of anti-VEGF agents in patients with nAMD. The results of the SLR were included in a network meta-analysis (NMA) comparing aflibercept 8 mg to other anti-VEGF treatments in nAMD, considering a 1-year time horizon. Treatment efficacy was assessed based on the change in best-corrected visual acuity (BCVA) from baseline, the proportion of patients gaining or losing 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and changes in anatomical outcomes measured as change in central retinal thickness (CRT) or central subfield thickness (CST). Safety was assessed considering the incidence of ocular and non-ocular adverse events. Treatment burden was defined as the mean number of intravitreal injections over the study period.</p><p><strong>Results: </strong>The base-case NMA involving 21 studies did not show significant differences between aflibercept 8 mg and comparators regarding BCVA change from baseline and proportion of patients with a gain or loss of ≥ 15 letters. On the anatomical endpoints, aflibercept 8 mg was associated with statistically significant improvement in CRT/CST change from baseline compared with ranibizumab in fixed and pro re nata regimens. No significant differences were identified versus the other anti-VEGF. The analysis of the safety outcomes did not identify any significant differences between aflibercept 8 mg and any of the comparators. During the first year of treatment, patients treated with aflibercept 8 mg (following 12- or 16-week injection intervals) received on average 5.9 and 5.1 injections, respectively. For the same period, patients treated with faricimab received from 6.2 to 6.7 injections, patients treated with ranibizumab from 7.62 to 12.14 injections, and patients treated with aflibercept 2 mg up to 7.67 injections.</p><p><strong>Conclusion: </strong>Aflibercept 8 mg demonstrates a comparable efficacy and safety to currently available anti-VEGF treatments for nAMD, with the potential added benefit of requiring fewer injections. These results suggest that aflibercept 8 mg could be a favourable treatment option for nAMD, achieving sustained disease control while alleviating the burden of injections on patients, caregivers, and healthcare providers.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study.","authors":"Jason Bacharach, Shane R Kannarr, Anthony Verachtert, Preeya K Gupta, Moataz Razeen, Megan E Cavet, Jason L Vittitow, Jacob Lang, Thomas M Chester, Jillian F Ziemanski, Darrell E White","doi":"10.1007/s40123-025-01097-z","DOIUrl":"https://doi.org/10.1007/s40123-025-01097-z","url":null,"abstract":"<p><strong>Introduction: </strong>Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms of dry eye disease (DED) and targets excessive tear evaporation. This study evaluated patient-reported outcomes early in treatment with PFHO.</p><p><strong>Methods: </strong>This prospective, multicenter, open-label, phase 4 study enrolled adults with a history of DED for ≥ 6 months. PFHO was instilled in both eyes four times daily for 14 days. Patients completed early outcome surveys during four clinic visits (day 1 [pretreatment; 5 and 60 min post-PFHO instillation] and days 3, 7, and 14). Symptom severity, symptom frequency, and treatment satisfaction were rated on visual analog scales (range 0-100). The primary endpoint was mean change from baseline in overall DED symptom severity at day 7. Secondary endpoints included change in severity of individual DED symptoms (eye dryness, blurred vision, eye irritation, light sensitivity, eye tiredness, burning/stinging, eye itching, eye pain); change in frequency (measured as percentage of time experienced) of the most bothersome symptom, awareness of dry eye symptoms, and fluctuation in quality of vision; and treatment satisfaction.</p><p><strong>Results: </strong>Ninety-nine patients enrolled (85.9% female; age range 35-81 years). The primary endpoint was met: mean (SD) overall symptom severity decreased significantly from 72.1 (17.0) at baseline to 27.8 (22.3) at day 7 (mean change, - 44.5; P < 0.0001). Mean (SD) percentage of time experiencing the most bothersome symptom decreased from 77.9% at baseline to 34.7% at day 14 (P < 0.0001). Significant reductions in severity and frequency also were observed for all symptoms at all postbaseline assessments (P < 0.0001). Median ratings of treatment satisfaction were 83.0 at day 3, 86.0 at day 7, and 90.0 at day 14.</p><p><strong>Conclusion: </strong>Early in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptom frequency and severity. Treatment satisfaction with PFHO was high.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT06309953.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Efficacy of Large Language Models in Guiding Treatment Decisions for Pediatric Refractive Error.","authors":"Daohuan Kang, Hongkang Wu, Lu Yuan, Wenyue Shen, Jia Feng, Jiao Zhan, Andrzej Grzybowski, Wen Sun, Kai Jin","doi":"10.1007/s40123-025-01105-2","DOIUrl":"https://doi.org/10.1007/s40123-025-01105-2","url":null,"abstract":"<p><strong>Introduction: </strong>Effective management of pediatric myopia, which includes treatments like corrective lenses and low-dose atropine, requires accurate clinical decisions. However, the complexity of pediatric refractive data, such as variations in visual acuity, axial length, and patient-specific factors, pose challenges to determining optimal treatment. This study aims to evaluate the performance of three large language models in analyzing these refractive data.</p><p><strong>Methods: </strong>A dataset of 100 pediatric refractive records, including parameters like visual acuity and axial length, was analyzed using ChatGPT-3.5, ChatGPT-4o, and Wenxin Yiyan, respectively. Each model was tasked with determining whether intervention was needed and subsequently recommending a treatment (eyeglasses, orthokeratology lens, or low-dose atropine). The recommendations were compared to professional optometrists' consensus, rated on a 1-5 Global Quality Score (GQS) scale, and evaluated for clinical safety utilizing a three-tier accuracy assessment.</p><p><strong>Results: </strong>ChatGPT-4o outperformed both ChatGPT-3.5 and Wenxin Yiyan in determining intervention needs, with an accuracy of 90%, significantly higher than Wenxin Yiyan (p < 0.05). It also achieved the highest GQS of 4.4 ± 0.55, surpassing the other models (p < 0.001), with 85% of responses rated as \"good\" ahead of ChatGPT-3.5 (82%) and Wenxin Yiyan (74%). ChatGPT-4o made only eight errors in recommending interventions, fewer than ChatGPT-3.5 (12) and Wenxin Yiyan (15). Additionally, it performed better with incomplete or abnormal data, maintaining higher quality scores.</p><p><strong>Conclusion: </strong>ChatGPT-4o showed better accuracy and clinical safety, making it a promising tool for decision support in pediatric ophthalmology, although expert oversight is still necessary.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance and Safety of a Sodium Hyaluronate, Xanthan Gum, and Osmoprotectants Ophthalmic Solution in the Treatment of Dry Eye Disease: An Observational Clinical Investigation.","authors":"Mercedes Molero Senosiaín, Barbara Burgos-Blasco, Pilar Perez-García, Álvaro Sánchez-Ventosa, Marta Villalba-González, María Dolores López Pérez, José Carlos Díaz, Vanesa Díaz-Mesa, Alberto Villarrubia Cuadrado, Enrique Artiaga Elordi, Jose Manuel Larrosa Poves, Alejandro Blasco, Antonio Mateo, Claudine Civiale, Laura Bonino, Antonio Cano-Ortiz","doi":"10.1007/s40123-025-01099-x","DOIUrl":"https://doi.org/10.1007/s40123-025-01099-x","url":null,"abstract":"<p><strong>Introduction: </strong>Dry eye disease (DED) is characterized by an imbalance in the tear film, resulting in symptoms such as dryness, redness, and discomfort. The management of DED involves tear supplements, medications, or surgery in severe cases. To evaluate the clinical performance and safety of a hypotonic ophthalmic solution containing sodium hyaluronate 0.2%, xanthan gum 0.2%, and osmoprotectants (glycine and betaine) for treating DED.</p><p><strong>Methods: </strong>This multicenter, prospective, observational clinical investigation included 35 subjects treated with one drop of the ophthalmic solution four times daily. Evaluations were conducted at baseline, on day 14, and at 1 and 3 months. The investigation assessed corneal and conjunctival fluorescein staining (NEI score), hyperemia index (Keratograph®), fluorescein tear film break-up time (TFBUT), best-corrected visual acuity, dry eye symptoms (SANDE), and quality of life (DEQS). Safety was monitored through adverse events, intraocular pressure measurements, and the Investigator Global Assessment of Safety.</p><p><strong>Results: </strong>Subjects were predominantly female (93.9%), with an average age of 59.9 ± 13.8 years. The ophthalmic solution significantly reduced keratitis lesions with global NEI score decreasing from baseline at 1 month (- 6.67 ± 4.6, p = 0.001) and 3 months (- 7.61 ± 4.0 points; p = 0.001). Conjunctival hyperemia improved significantly after 1 month (- 0.34 ± 0.7 points; p = 0.027), while fluorescein tear film stability increased significantly at 1 (1.85 ± 3.1 s; p = 0.002) and 3 months (1.98 ± 3.4 s; p = 0.001). Symptoms also improved significantly (p = 0.001) at 1 and 3 months (- 29.37 ± 22.2 points and - 26.41 ± 24.0 points, respectively), as did quality of life (- 20.81 ± 15.6 points at 1 month and - 18.43 ± 19.3 points at 3 months; p = 0.001 for both). The safety profile was very good, with no adverse events (only mild ocular discomfort reported in 14.3% of subjects).</p><p><strong>Conclusions: </strong>The ophthalmic solution effectively improved DED symptoms and signs, enhancing patients' quality of life while maintaining a good safety profile.</p><p><strong>Trial registration number: </strong>NCT05778942.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Advances in AI-Assisted Analysis of Fundus Fluorescein Angiography (FFA) Images: From Detection to Report Generation.","authors":"Tao Yu, An Shao, Hongkang Wu, Zichang Su, Wenyue Shen, Jingxin Zhou, Xingxi Lin, Danli Shi, Andrzej Grzybowski, Jian Wu, Kai Jin","doi":"10.1007/s40123-025-01109-y","DOIUrl":"https://doi.org/10.1007/s40123-025-01109-y","url":null,"abstract":"<p><p>Fundus fluorescein angiography (FFA) serves as the current gold standard for visualizing retinal vasculature and detecting various fundus diseases, but its interpretation is labor-intensive and requires much expertise from ophthalmologists. The medical application of artificial intelligence (AI), especially deep learning and machine learning, has revolutionized the field of automatic FFA image analysis, leading to the rapid advancements in AI-assisted lesion detection, diagnosis, and report generation. This review examined studies in PubMed, Web of Science, and Google Scholar databases from January 2019 to August 2024, with a total of 23 articles incorporated. By integrating current research findings, this review highlights crucial breakthroughs in AI-assisted FFA analysis and explores their potential implications for ophthalmic clinical practice. These advances in AI-assisted FFA analysis have shown promising results in improving diagnostic accuracy and workflow efficiency. However, further research is needed to enhance model transparency and ensure robust performance across diverse populations. Challenges such as data privacy and technical infrastructure remain for broader clinical applications.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Precision and Clarity with New Digital Color Assistant in 3D Heads-Up Vitreoretinal Surgery.","authors":"Rodolfo Mastropasqua, Alberto Quarta, Maria Ludovica Ruggeri, Leonardo Mastropasqua","doi":"10.1007/s40123-025-01106-1","DOIUrl":"https://doi.org/10.1007/s40123-025-01106-1","url":null,"abstract":"<p><strong>Introduction: </strong>To describe the advantages of the ARTEVO^® 850 digital color assistant (DCA) for enhancing visualization during vitreoretinal surgery.</p><p><strong>Methods: </strong>All surgical procedures were conducted under the expertise of a single surgeon utilizing the ARTEVO^® 850 heads-up microscope from ZEISS. During the surgeries, images were contemporaneously recorded with and without the application of the DCA across key phases: core vitrectomy, peripheral vitrectomy, epiretinal membrane (ERM) peeling, and internal limiting membrane (ILM) peeling. This approach enabled a direct comparison to evaluate the impact of the filter on visualization quality during each specific surgical maneuver.</p><p><strong>Results: </strong>The application of the \"vitrectomy blue\" filter on the ARTEVO^® 850 surgical microscope provided advantages, particularly during core and peripheral vitrectomy. The \"vitrectomy blue\" filter improved visualization of the vitreous, allowing for clearer identification and removal of residual vitreous strands and opacities. In surgeries involving ERM, the \"peeling blue\" filter provided enhanced contrast and clarity in visualizing the membrane, facilitating thorough peeling. Furthermore, when used in conjunction with dye staining techniques, it further amplified the visualization of ERM in high myopic eyes. This combination reduced the need for additional re-staining during surgery, streamlining the procedure and potentially minimizing intraoperative complications related to dye toxicity. In macular hole surgery, the \"peeling blue\" filter contributed to improving the characterization and delineation of the hole edges and surrounding tissues.</p><p><strong>Conclusions: </strong>The ARTEVO^® 850 DCA can potentially enhance tissue visualization during vitreoretinal surgeries, particularly in scenarios with compromised visibility. Our observation underscored the efficacy of the blue filter in improving the clarity and contrast of vitreous, ERM and macular hole visualization. This enhancement was particularly evident when the DCA was used in combination with dye staining techniques, which further improved the visualization of ERM in high myopic eyes.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Sticks for Routine Ophthalmic Surgery: A Randomized Controlled Monocentric Trial.","authors":"Isaak Fischinger, Manfred Tetz, Angela Odame, Heidi Kulas, Martin Abel","doi":"10.1007/s40123-025-01107-0","DOIUrl":"https://doi.org/10.1007/s40123-025-01107-0","url":null,"abstract":"<p><strong>Introduction: </strong>Ocular sticks are used to absorb fluids during ophthalmic surgeries. Hence, this prospective study was conducted to evaluate the clinical performance, safety, and usability of Pro-optha^® Ocular Sticks in comparison to an alternative device under the conditions of routine ophthalmic surgeries.</p><p><strong>Methods: </strong>Patients requiring eye surgery were randomly allocated into two equal groups, with the investigational device, Pro-ophta^® Ocular Sticks, as the intervention group (IG) and the alternative stick as the comparator group (CG). Two types of surgery were performed. The study is also registered on the German Clinical Trials Register with ID DRKS00025690.</p><p><strong>Results: </strong>106 patients were included in the analyses. In both treatment groups, the investigator's/surgeon's general user satisfaction was rated as either \"good\" or \"very good.\" The non-inferiority hypothesis that the Pro-ophta^® Ocular Stick is not rated worse in satisfaction than the alternative device was confirmed with statistical significance (p = 0.0005). At least 98.12% were rated as \"good\" and \"very good\" in both treatment groups for the additional endpoints. Pro-ophta^® Ocular Stick was rated better for almost all the additional endpoints and within the surgery subgroups. The mean number of sticks and surgery duration were 3.5 ± 2.74 and 11.5 (± 8.88) min, respectively, with a positive correlation (r = 0.580) for the Pro-ophta^® Ocular Stick and 3.9 ± 2.45 and 9.5 (± 5.90) min, respectively, with a positive correlation (r = 0.025) for the alternative device. No device-related adverse events occurred.</p><p><strong>Conclusions: </strong>Effective ocular sticks play an instrumental role in the outcome of ophthalmic surgeries. The investigational device demonstrated efficiency, yielding good surgical results, usability, and an exceptionally good safety profile.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}